These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25132665)

  • 21. 5'-nor carbocyclic ribavirin.
    Tuncbilek M; Schneller SW
    Nucleosides Nucleotides Nucleic Acids; 2003 Nov; 22(11):1995-2001. PubMed ID: 14680022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.
    Gardelli C; Attenni B; Donghi M; Meppen M; Pacini B; Harper S; Di Marco A; Fiore F; Giuliano C; Pucci V; Laufer R; Gennari N; Marcucci I; Leone JF; Olsen DB; MacCoss M; Rowley M; Narjes F
    J Med Chem; 2009 Sep; 52(17):5394-407. PubMed ID: 19725579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ribavirin: is it a mutagen for hepatitis C virus?
    Perelson AS; Layden TJ
    Gastroenterology; 2007 May; 132(5):2050-2. PubMed ID: 17484896
    [No Abstract]   [Full Text] [Related]  

  • 24. Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin.
    Wu JZ; Larson G; Hong Z
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4006-8. PubMed ID: 15388466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nm 283, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.
    Pierra C; Benzaria S; Amador A; Moussa A; Mathieu S; Storer R; Gosselin G
    Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):767-70. PubMed ID: 16248033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nucleotide prodrugs for HCV therapy.
    Sofia MJ
    Antivir Chem Chemother; 2011 Aug; 22(1):23-49. PubMed ID: 21860070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding the molecular targets for new therapeutical agents in hepatitis c infection.
    Vagu C; Sultana C; Ruţă S
    Roum Arch Microbiol Immunol; 2013; 72(1):5-24. PubMed ID: 23947011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isosteric ribavirin analogues: Synthesis and antiviral activities.
    Zhurilo NI; Chudinov MV; Matveev AV; Smirnova OS; Konstantinova ID; Miroshnikov AI; Prutkov AN; Grebenkina LE; Pulkova NV; Shvets VI
    Bioorg Med Chem Lett; 2018 Jan; 28(1):11-14. PubMed ID: 29173944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of imidazole N-H substituted amide prodrugs as inhibitors of hepatitis C virus replication.
    Zong X; Cai J; Chen J; Wang P; Zhou G; Chen B; Li W; Ji M
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3147-50. PubMed ID: 26077493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleotide prodrugs for the treatment of HCV infection.
    Sofia MJ
    Adv Pharmacol; 2013; 67():39-73. PubMed ID: 23885998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benzohydroxamic acids as potent and selective anti-HCV agents.
    Kozlov MV; Kleymenova AA; Romanova LI; Konduktorov KA; Smirnova OA; Prasolov VS; Kochetkov SN
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5936-40. PubMed ID: 24035094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.
    Mori K; Hiraoka O; Ikeda M; Ariumi Y; Hiramoto A; Wataya Y; Kato N
    Hepatology; 2013 Oct; 58(4):1236-44. PubMed ID: 23532970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver.
    Dong Z; Li Q; Guo D; Shu Y; Polli JE
    J Pharm Sci; 2015 Sep; 104(9):2864-76. PubMed ID: 25645375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential applications of siRNA in hepatitis C virus therapy.
    Smolic R; Volarevic M; Wu CH; Wu GY
    Curr Opin Investig Drugs; 2006 Feb; 7(2):142-6. PubMed ID: 16499284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.
    Tang YB; Peng ZG; Liu ZY; Li YP; Jiang JD; Li ZR
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6350-3. PubMed ID: 17888662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver-targeted prodrugs of 2'-C-methyladenosine for therapy of hepatitis C virus infection.
    Hecker SJ; Reddy KR; van Poelje PD; Sun Z; Huang W; Varkhedkar V; Reddy MV; Fujitaki JM; Olsen DB; Koeplinger KA; Boyer SH; Linemeyer DL; MacCoss M; Erion MD
    J Med Chem; 2007 Aug; 50(16):3891-6. PubMed ID: 17636948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The phosphoramidate ProTide approach greatly enhances the activity of beta-2'-C-methylguanosine against hepatitis C virus.
    McGuigan C; Perrone P; Madela K; Neyts J
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4316-20. PubMed ID: 19523820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macromolecular prodrugs for controlled delivery of ribavirin.
    Kryger MB; Smith AA; Wohl BM; Zelikin AN
    Macromol Biosci; 2014 Feb; 14(2):173-85. PubMed ID: 24105953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
    Pár A
    Orv Hetil; 2010 Dec; 151(50):2045-56. PubMed ID: 21126947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis of 9-(2-beta-C-methyl-beta-d-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication.
    Ding Y; Girardet JL; Hong Z; Lai VC; An H; Koh YH; Shaw SZ; Zhong W
    Bioorg Med Chem Lett; 2005 Feb; 15(3):709-13. PubMed ID: 15664842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.